PacBio to Present at Upcoming Investor Conferences
Rhea-AI Summary
PacBio (NASDAQ: PACB), a developer of high-quality sequencing solutions, has announced its participation in two upcoming investor conferences. Management will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 2:30 PM ET in Boston, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025, at 12:20 PM ET in New York.
Investors can access live webcasts of both presentations through PacBio's investor relations website, with replays available for at least 30 days after each event.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PACB
On the day this news was published, PACB declined 2.82%, reflecting a moderate negative market reaction. Argus tracked a peak move of +13.9% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $11M from the company's valuation, bringing the market cap to $378.11M at that time.
Data tracked by StockTitan Argus on the day of publication.
MENLO PARK, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
- Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 2:30 PM ET in Boston, MA
- Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at 12:20 PM ET in New York, NY
Live webcasts of the events can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcasts will be available for at least 30 days following the event.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
Todd Friedman
ir@pacb.com
Media:
pr@pacb.com
